aspirin has been researched along with ponatinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Usui, N | 1 |
| Abruzzese, E; Albano, F; Annunziata, M; Attolico, I; Baratè, C; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Castagnetti, F; Cattaneo, D; De Gregorio, F; Elena, C; Foà, R; Fozza, C; Galimberti, S; Gozzini, A; Gugliotta, G; Iurlo, A; La Nasa, G; Luciano, L; Mulas, O; Orlandi, EM; Pirillo, F; Pregno, P; Scaffidi, L; Scalzulli, E; Sgherza, N; Stagno, F; Trawinska, MM | 1 |
2 other study(ies) available for aspirin and ponatinib
| Article | Year |
|---|---|
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk | 2017 |
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiology; Coronary Occlusion; Decision Support Systems, Clinical; Female; Humans; Hypertension; Imidazoles; Incidence; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Pyridazines; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2019 |